In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Experiments: Pharmas Get Creative in Germany

Executive Summary

As Germany's insurers try out new drug reimbursement tactics, innovative pharmas have responded with novel, brand-boosting payor deals of their own. The evolution of these payor-pharma deals in Germany should inform reimbursement strategies elsewhere--including in the US where similar trends are starting to emerge.
Advertisement

Related Content

A Year After It Wins Ratiopharm, Teva Reaps Rewards in Europe
Pay-for-Performance in the US: What Could Work, What Won't
Best of the Blog: IN VIVO, October 2009
Amgen's D-mab: The New EPO
The Cost-Sharing Solution: The New NICE Ticket
Amgen's D-mab: The New EPO
Novartis Launches Extavia For Practice In MS Market, Preparing For FTY720
German Health Reform Law Could Shake Up Pharmaceutical Market
German Health Care Reform: Raising the Innovation Threshold
German Health Care Reform: Raising the Innovation Threshold

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel